Clinical research
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.
Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond its newly-approved aducanumab has hit a clinical snag after gosuranemab failed.
Biopharma and life sciences companies from across the globe provide updates on their business operations and pipelines.
The new data shows REGEN-COV reduced the risk of death in hospitalized patients unable to mount their own immune response by 20%.
The StrataGraft is designed to help heal patients who have received thermal burns that would ultimately require a skin graft. Here’s everything about it.
Eli Lilly and Company announced Tuesday the launch of a head-to-head study to compare once-monthly injectable Emgality® (galcanezumab-gnlm) with Nurtec® ODT (rimegepant) for the prevention of migraine.
The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
The company noted it would continue to assess the STAR study’s complete data set before confirming its future plans for clinical development of timrepigene emparvovec.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 15, 2021.
PRESS RELEASES